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 Purpose
Although studies regarding dental developmental disturbances after childhood cancer treat-
ment have increased, they have many limitations. Studies analyzing the significance of 
independent clinical risk factors with regard to the dental health status are also rare. We
aimed to investigate the risk factors for dental developmental disturbances, particularly 
severe disturbances, in childhood cancer survivors (CCS).
Materials and Methods
Oral examinations and retrospective reviews of medical and panoramic radiographs were
performed for 196 CCS (mean age, 15.6 years). Cancer type, age at diagnosis, treatment
modality, type and accumulated dose of administered drugs, and dose and site of radiation
were recorded. Dental developmental disturbances were diagnosed using panoramic radi-
ographs and graded for severity according to the Modified Dental Defect Index (MDDI). 
Descriptive statistics and multivariate analyses were performed to determine the association
between dental abnormalities and clinical factors.
Results
In total, 109 CCS (55.6%) exhibited at least one dental anomaly, and the median value of
MDDI was 2.5. Microdontia (30.6%) was the most prevalent anomaly, followed by tooth
agenesis (20.4%), V-shaped roots (14.8%), and taurodontism (10.2%). Multivariate analysis
revealed that a young age at diagnosis ( 3 years), a history of hematopoietic stem cell
transplantation, the use of multiple classes of chemotherapeutic agents ( 4 classes), and
the use of heavy metal agents were significant risk factors for severe dental disturbances.
Conclusion
CCS with any of the above risk factors for severe developmental disturbances should be
comprehensively followed up to minimize adverse consequences to their dental develop-
ment and preserve their future dental health.
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Introduction
The survival of patients with childhood cancer has 
increased because of current multimodal therapies, and 
research has been increasingly focusing on the future quality
of life of these survivors. The long-term dental effects of can-
cer therapy in children include several irreversible develop-
mental anomalies, such as tooth agenesis, microdontia,
enamel hypoplasia, disturbed root development, and tau-
rodontism [1]. More than 90% of childhood cancer survivors
(CCS) exhibit an oral complication of some type [2].
Both chemotherapeutic agents and radiation therapy,
which should ideally eradicate only tumor cells and cause
minimal damage to normal tissue, lack specificity, and this
results in the occurrence of dental and facial developmental
anomalies. The severity of effects on dentofacial structures
was found to be associated with the stage of odontogenesis,
age at cancer diagnosis, type of treatment received, and dose
and field of irradiation [3]. Chemotherapy and radiation ther-
apy in children have negative effects on dental development,
which is a unique process that occurs during the first 15-16
years of life. Existing reports have found that patients treated
with chemotherapy at less than 5 years of age may be at a
greater risk for dental anomalies because of the proliferation
of dental stem cells during this period [4].
Although there are multiple studies investigating dental
developmental disturbances after childhood cancer treat-
ment, they have many limitations, including a small number
of participants, the use of questionnaires instead of clinical
examinations, and the use of registry databases [5,6]. Studies
analyzing the significance of independent clinical risk factors
with regard to dental health status are also rare. In the pres-
ent study, we used comprehensive clinical examinations and
panoramic radiographs to evaluate the severity of dental 
developmental disturbances in CCS in an established long-
term follow-up clinic using a newly developed scoring sys-
tem. 
Materials and Methods
1. Study population
In total, 196 CCS who visited the long-term follow-up
clinic in the childhood cancer center at Yonsei Cancer Center,
Yonsei University Health System between December 13, 2014
and October 1, 2016 were included in this study. The mini-
mum follow-up duration was 2 years after the completion of
childhood cancer therapy. The primary outcome was the 
occurrence of dental complications at least 2 years after the
completion of cancer therapy.
2. Demographics and evaluated risk factors
Oral examinations were performed in conjunction with a
retrospective review of medical and panoramic radiography
data; the cancer type, age at cancer diagnosis, treatment
modality, type and accumulated dose of administered drugs,
and dose and site of radiation were recorded. The patients
were divided into three groups according to the age at cancer
diagnosis: youngest ( 3 years old), middle (3-5 years), and
oldest ( 5 years). The class of chemotherapeutic agents was
defined by the mechanisms of action for each agent. The total
number of chemotherapeutic agent classes used for each sur-
vivor was recorded to estimate the toxicity of chemotherapy;
“multiple classes” was defined as  4 classes. The radiation
dose was defined as the maximal dose of radiation delivered
to specific body regions, including the head and neck.
3. Diagnosis of dental developmental disturbances
Dental developmental disturbances were diagnosed using
dental examinations, panoramic radiography, and dental his-
tories. Clinical and radiographic data were reviewed by 
pediatric dental specialists. Tooth agenesis was defined as
the congenital absence of a permanent tooth or tooth germ
(third molars were excluded). Microdontia was defined as a
tooth size that was smaller than normal (third molars and the
maxillary lateral incisor, which is commonly affected, were
Table 1. Classification of dental developmental disturbances with the Modified Dental Defect Index (MDDI)
Site Classification MDDI
Crown Normal crown development 0
Mild enamel hypoplasia diagnosed as developmental enamel defect 1
Severe enamel hypoplasia diagnosed as notches on proximal surfaces 2
Root Normal root development, R/C ratio > 1.6 0
Taurodontism (taurodontic index > 20) 1
Arrested root development with shortened tapered V-shaped roots 1
(R/C ratio=0.8-1.6; greater than 50% normal root length)
Arrested root development with shortened blunted (U-shaped) roots 3
(R/C ratio < 0.8; less than 50% normal root length)
Total arrested root development 5
Crown and root Microdontia (mesiodistal crown size was about half or less than the expected tooth size) 4
Tooth agenesis 6
In multi-rooted teeth, the longest root was used in the calculation. R/C ratio, relative ratio between root (R) and crown (C)
length.
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excluded). The criteria for classifying data as undetermined
were as follows: ongoing tooth development with an unclear
final morphology, absence of teeth that are not categorized
in the agenesis group at a young age, and generally unreli-
able appearance on panoramic view. With regard to tooth
agenesis, a tooth was not considered missing before a certain
age as follows: first premolar, < 5 years; second premolar, 
< 6 years; and second molar, < 7 years.
4. Modified Dental Defect Index
We developed the Modified Dental Defect Index (MDDI)
to describe the severity of damage to the dentition in the
present study (Table 1). This index system is a modified ver-
sion of the defect index and the dental disturbance classifi-
cation and severity rating scale proposed by Sonis et al. [4]
and Holtta et al. [7]. The MDDI combines abnormalities in
Fig. 1.  A panoramic radiograph (A) and schematic presentation (B) of the method of calculation of the Modified Dental Defect
Index (MDDI) score for a patient (7 years and 11 months, male) with Ewing’s sarcoma. The patient received 45 Gy of radiation
to the ethmoid region at 3 years and 2 months of age and chemotherapy with doxorubicin (300 mg/m2) at 1 year and 7 months
of age. Twelve permanent teeth are missing, and the development of all present teeth is severely affected. The total MDDI
score is 130.
A
B
Upper right Upper left
Lower right Lower left
Tooth number
MDDI
18
-
17
6
16
5
15
6
14
-
13
6
12
4
11
5
21
5
22
4
23
6
24
-
25
6
26
5
27
6
28
-
MDDI
Tooth number
-
48
6
47
5
46
6
45
6
44
-
43
5
42
5
41
5
31
5
32
-
33
6
34
6
35
5
36
6
37
-
38
Cancer Res Treat. 2018;50(3):926-935
928 CANCER  RESEARCH  AND  TREATMENT
root length, crown calcification, microdontia, and tooth age-
nesis, thus representing the overall damage to the permanent
dentition with a single index figure. The MDDI was finally
calculated by adding the score for each permanent tooth as
shown in Fig 1. The disturbances in each patient were cate-
gorized as normal (MDDI, 0), moderately abnormal (1 
MDDI < 14), and severely abnormal (MDDI  14). The cut-
off (MDDI, 14) score was set to the median value for the sur-
vivors with an abnormal MDDI score ( 1).
5. Statistical analysis
Dental developmental disturbances and clinical risk factors
were evaluated using exact chi-square tests, and Kruskal–
Wallis tests. Logistic regression models were used to assess
the association between the risk factors and severely abnor-
mal disturbances. Factors that were significant in the univari-
ate analysis and clinically meaningful variables were selected
for the multivariate analysis. All statistical analyses were per-
formed using IBM SPSS ver. 23.0 (IBM SPSS Statistics, IBM
Corp., Armonk, NY) and OriginPro 2016 software (Origin-
Lab, Northampton, MA).
6. Ethical statement
All procedures performed in studies involving human par-
ticipants were in accordance with the ethical standards of the
Institutional Review Board of Yonsei University Dental Hos-
pital (approval number: 2-2015-0010). The informed consent
was waived.
Results
1. Patient characteristics
Among the 196 survivors, 127 were boys and 69 were girls.
The median age at cancer diagnosis and treatment comple-
tion was 4.7 and 7.1 years, respectively. The median time
since the completion of cancer therapy was 6.9 years (2.1-
22.5). The most prevalent type of cancer was acute lym-
phoblastic leukemia (36.2%) (Table 2). The proportion of
patients who received chemotherapy was 99.5%, and the 
median number of agent classes was seven. There was a sig-
nificant difference in the type of drug treatment received 
between the three age groups, which included enzymes,
alkylating agents, antimetabolites, corticosteroids, and 
anthracyclines (S1 Table). Radiotherapy was administered to
67 patients (34.2%), with the dose ranging from 6.0 to 70.2
Gy. Radiotherapy use was most prevalent in the oldest group
(47.9%), followed by the middle (27.3%) and youngest
(17.2%) groups. Forty-seven patients (24.0%) underwent
hematopoietic stem cell transplantation (HSCT); the median
age at HSCT was 6.1 (0.6-14.8) years (S2 Table).
Characteristic All Youngest Middle Oldest p-value( 3 yr) (3-5 yr) ( 5 yr)
Sex (male:female) 127:69 44:20 30:15 53:34
Age at diagnosis (yr) 4.7 (0-16.4) 1.6 (0-3.0) 4.0 (3.0-4.9) 8.6 (5.0-16.4) < 0.001
Age at completion (yr) 7.1 (0.4-16.9) 3.0 (0.4-11.0) 6.3 (3.9-13.2) 10.0 (5.9-16.9) < 0.001
Treatment term 1.1 (0-10.25) 0.9 (0-10.25) 3.0 (0.3-8.5) 1.0 (0-6.8) 0.003
Evaluation age 14.9 (4.6-33.9) 12.7 (4.6-25.2) 13.1 (6.4-29.4) 17.4 (9.4-33.9) < 0.001
Follow-up term 6.9 (2.1-22.5) 9.5 (2.3-21.8) 7.3 (2.1-22.5) 6.1 (2.1-22.0) 0.001
Diagnosis
ALL 71 (36.2) 15 (23.4) 28 (63.6) 28 (31.8) < 0.001
AML 7 (3.6) 2 (3.1) 0 ( 5 (5.7) 0.246
Lymphoma 23 (11.7) 6 (9.4) 4 (9.1) 13 (14.8) 0.490
Brain tumor 22 (11.2) 3 (4.7) 1 (2.3) 18 (20.5) 0.001
Sarcoma 18 (9.2) 4 (6.3) 3 (6.8) 11 (12.5) 0.347
Abdomen 37 (18.9) 23 (35.9) 6 (13.6) 8 (9.1) < 0.001    
Others 18 (9.2) 11 (17.2) 2 (4.5) 5 (5.7) 0.025
Table 2. Demographics of the study population
Values are presented as median (range) or number (%). Others indicate Langerhans cell histiocytosis, aplastic anemia, hemo-
phagocytic lymphohistiocytosis, hemophagocytic syndrome. ALL, acute lymphoblastic leukemia; AML, acute myelogenous
leukemia. 
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2. Prevalence of dental developmental disturbances
The panoramic radiographs of 87 patients (44.4%) showed
no dental abnormalities at the most recent examination; those
of the remaining 109 patients (55.6%) showed at least one 
abnormality. Microdontia (30.6%) was the most prevalent,
followed by tooth agenesis (20.4%), V-shaped roots (14.8%),
and taurodontism (10.2%) (Table 3). In the youngest group,
42.2% of patients exhibited tooth agenesis or microdontia.
Abnormal root development was less frequently observed in
Characteristic All Youngest Middle Oldest p-value( 3 yr) (3-5 yr) ( 5 yr)
Normal 87 (44.4) 13 (20.3) 19 (43.2) 55 (62.5) < 0.001
Dental disturbances 109 (55.6) 51 (79.7) 25 (56.8) 33 (37.5) < 0.001
Tooth agenesis 40 (20.4) 25 (39.1) 7 (15.9) 8 (9.1) < 0.001
Microdontia 60 (30.6) 37 (57.8) 13 (29.5) 10 (11.4) < 0.001
Mild enamel hypoplasia 10 (5.1) 4 (6.3) 2 (4.5) 4 (4.5) 0.879
Severe enamel hypoplasia 14 (7.1) 11 (17.2) 3 (6.8) 0 ( < 0.001
V-shaped root 29 (14.8) 13 (20.3) 8 (18.2) 8 (9.1) 0.121
U-shaped root 19 (9.7) 4 (6.3) 5 (11.4) 10 (11.4) 0.525
Total arrested root development 1 (0.5) 1 (1.6) 0 ( 0 ( 0.355
Taurodontism 20 (10.2) 7 (10.9) 8 (18.2) 5 (5.7) 0.080
Total MDDI score 2.5 (0-130) 18 (0-130) 6 (0-44) 0 (0-36) < 0.001
Table 3. Prevalence of dental developmental disturbances in childhood cancer survivors (overall cohort and different age
groups)
Values are presented as number (%) and median (range). MDDI, Modified Dental Defect Index. 
Fig. 2.  (A) Proportions of patients with tooth agenesis, microdontia, abnormal root development, and combined anomalies
in the three age groups of childhood cancer survivors (youngest,  3 years; middle, 3-5 years; oldest,  5 years). The prevalence
of agenesis or microdontia is the highest in the youngest group, while that of abnormal root development exhibits a tendency
to increase in the older groups. (B) Distribution of teeth affected by tooth agenesis and microdontia. The data show that 
microdontia is most common in the maxillary second premolars and second molars, while tooth agenesis is most common in
the maxillary and mandibular second premolars. U1, upper (maxillary) central incisor.
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this group compared with the other groups (1.6%) (Fig. 2A).
In the oldest group, abnormal root development (18.2%) was
more prevalent than agenesis or microdontia (13.6%), while
the prevalence of combined disturbances (3.4%) in the
youngest group was markedly lower than that in the other
groups. The most common teeth exhibiting agenesis were the
mandibular (22.8%) and maxillary (17.7%) second premolars.
Microdontia was the most prevalent in the maxillary second
premolar (24.1%), followed by the maxillary second molar
(17.7%) (Fig. 2B).
Fig. 3.  Relationship between Modified Dental Defect Index (MDDI) scores and treatment factors in the three age groups of
childhood cancer survivors (youngest,  3 years; middle, 3-5 years; oldest,  5 years). (A) The MDDI score for the youngest
group is significantly different compared to the middle and oldest groups (p < 0.001). (B) The MDDI score is significantly
higher in the youngest group diagnosed with brain tumors (p=0.042). (C) The MDDI score is significantly higher in youngest
group treated with hematopoietic stem cell transplantation (p=0.001). (D) The MDDI score is significantly higher in youngest
group treated with head and neck radiation therapy at a dose of  40 Gy (p=0.002). (Continued to the next page)
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Fig. 3.  (Continued from the previous page) (E) The MDDI score is significantly higher in the youngest group receiving  4 classes
of chemotherapeutic agents (p=0.003). (F) The use of heavy metal agents significantly increases the MDDI score in the youngest
and middle groups (p=0.004 and p=0.037, respectively).
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Table 4. Multivariate analysis of potential risk factors for severely abnormal Modified Dental Defect Index (MDDI) compared
to normal MDDI group
Characteristic Odds ratio 95% Confidence interval p-value
Sex
Male vs. female 0.753 0.255-2.217 0.606 
Age at diagnosis
Youngest ( 3 yr) 265.757    37.037-1,906.915  < 0.001
Middle (> 3 yr and < 5 yr) 33.897 5.583-205.796  < 0.001
Oldest ( 5 yr) Reference 
Brain tumor
No vs. brain tumor 0.420   0.016-11.270 0.605 
HNRT dose
< 40 Gy vs.  40 Gy 2.442 0.122-48.983 0.560 
HSCT
Non-HSCT vs. HSCT 3.875 1.016-14.785 0.047
Multiple class of chemotherapeutic agents
< 4 class vs.  4 class 8.878    2.263-34.822  0.002
Use of heavy metal agents
No vs. yes 9.350    1.970-44.370 0.005
HNRT, head and neck radiation therapy; HSCT, hematopoietic stem cell transplantation.
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3. Clinical risk factors for dental developmental distur-
bances
The MDDI score was significantly higher in the youngest
group than the other two groups (p < 0.001). There was no
significant difference in the MDDI score between the other
two groups (p=0.396) (Fig. 3A). The presence of a brain tumor
and a history of HSCT were associated with an increased risk
for developmental anomalies, particularly in the youngest
group (p=0.042 and p=0.001, respectively) (Fig. 3B and C). In
addition, the MDDI score showed a significant increase with
the maximum head and neck radiation therapy (HNRT) dose
( 40 Gy and < 40 Gy) in the youngest group (p=0.002) 
(Fig. 3D). The use of  4 classes of chemotherapeutic agents
(p=0.003) and the use of heavy metal agents (p=0.004) also
demonstrated a significant association with an increased
MDDI score in the youngest group (Fig. 3E and F). The lin-
ear-by-linear association test was used to examine the linear
association between clinical risk factors and MDDI severity
outcomes. The use of heavy metal agents significantly 
affected moderate and severe dental defects (S3 Table). Com-
paring MDDI according to the age group and clinical risk fac-
tors, the score increased in patients with a history of HSCT,
heavy metal use, and tumor of the abdomen. Additional risk
factors were influenced by the youngest group, which 
included a history of  40 Gy HNRT, the use of alkylating
agents, and a diagnosis of brain tumor. A history of sarcoma
was a significant risk factor for dental defects in the middle
group (S4 Table).
4. Multivariate analysis of risk factors for severe dental 
developmental disturbances
Multivariate analysis revealed that a young age at diagno-
sis ( 3 years), a history of HSCT, the use of  4 classes of
chemotherapeutic agents, and the use of heavy metal agents
were significant risk factors for severely abnormal MDDI
scores (Table 4).
Discussion
We investigated the significant risk factors for dental 
developmental disturbances in CCS among different age
groups and found that childhood cancer treatment often 
results in developmental disturbances of permanent denti-
tion, with 55.6% of patients exhibiting at least one dental dis-
turbance. Depending on the age at cancer diagnosis and the
intensity of treatment, the dental abnormalities ranged from
tooth agenesis (20.4%) to microdontia (30.6%) and shortened
roots caused by the premature arrest of root formation.
In the present study, a young age at cancer diagnosis ( 3
years) was found to be the most important risk factor for den-
tal developmental anomalies. This finding suggests that
tooth development may be affected at any point prior to
complete maturation. Our age group classification was based
on the standard schedule for tooth development. Calcifica-
tion of the first premolars begins between 1.5 and 2 years of
age, while that of the second premolars and second molars
begins between 2 and 2.5 years and 2-2.5 and 3 years, respec-
tively. While other permanent teeth start hard tissue forma-
tion within 1 year of birth, premolars and the second molars
begin initial calcification 2 years after birth. Therefore, these
teeth are vulnerable to environmental factors such as cancer
treatment during their development. If teeth do not develop
at or near these times, they will grow abnormally, resulting
in tooth agenesis or microdontia. Between 3 and 5 years of
age, root development begins in teeth that develop early and
crown development is ongoing in teeth that develop late.
Cancer treatment administered during this period is believed
to cause disturbances to both crowns and roots. The present
study clearly demonstrates that the prevalence of tooth age-
nesis and microdontia decreases and that of abnormal root
development tends to increase with age. Previous studies
have shown that children treated before and approximately
5 years of age were at a high risk for dental disturbances due
to localized or systemic insults on ameloblasts and odonto-
blasts, which arrest dental growth [2,3]. Since the dental 
development process is very active between 3 and 5 years of
age, the high frequency of treatment-related dental abnor-
malities found in our study is not surprising. In contrast,
studies have suggested that the prevalence of dental devel-
opmental disturbances does not change with the age at can-
cer diagnosis [8,9]. These differences in findings are probably
caused by differences in the treatment protocol and the 
inclusion of small groups confined to a single diagnosis. 
Additionally, variations in the timing of tooth formation
could also be a possible reason.
Chemotherapeutic drugs can affect the development of
permanent teeth. The severity of tooth-related abnormalities
secondary to cancer treatment is related to the age at the time
of treatment, drug dosage, and treatment duration [10]. Dis-
turbed odontogenesis has been reported after the adminis-
tration of several chemotherapeutic agents, including
anthracyclines, cyclophosphamide, vincristine, and actino-
mycin D [11]. Interestingly, heavy metal agents such as cis-
platin and carboplatin also alter normal dental development.
These drugs are meant to interfere with replication and the
mitotic processes of cancer cells only, given the significant
side effects associated with healthy cell destruction [12]. In a
previous study, exposure to cisplatin elicited a minor 
decrease in precursor cells in the epithelial sheath and dental
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pulp stem cells, although the toxicity was similar to that
caused by other agents [13,14].
Radiation therapy is often implicated in development dis-
orders of the body; however, the minimum dose that alters
the development of the dentition remains unclear. Dental 
defects are more severe in children subjected to head and
neck radiotherapy and total body irradiation combined with
chemotherapy than in children subjected to chemotherapy
alone [8,9]. In a previous study, nine of 10 patients who 
received fractionated total body irradiation exhibited severe
root defects, whereas none of the patients who received
chemotherapy alone developed severe defects [15]. A previ-
ous study reported that a radiation dose of 4 Gy would affect
dental development [16], while another reported that doses
of 10 Gy and 30 Gy are enough to cause permanent damage
to mature ameloblasts and arrest dental development, 
respectively [17]. In the present study, we observed a signif-
icant increase in the MDDI score in a dose-dependent pattern
( 40 Gy) in children younger than 3 years. High-dose HNRT
was not found to be a significant factor in the multivariate
analysis because most patients who received  40 Gy were
above 5 years of age; radiotherapy was avoided in the
youngest group. However, in the univariate analysis, a head
and neck dose of  40 Gy influenced the MDDI score for the
youngest group, but not the score for the oldest group.
Therefore, the age of the patients was more important than
HNRT itself.
In the present study, the youngest patients who received
HSCT exhibited a statistically higher MDDI score compared
to the other groups, suggesting that HSCT may affect the
prevalence and severity of dental anomalies. Although rele-
vant studies regarding HSCT recipients are few, our patients
exhibited more dental anomalies than those who received
conventional chemotherapy. In our study, the most severe
disturbances in the root/crown ratio occurred in middle-
aged patients who received HSCT. The conditioning regimen
is considered the primary reason for severe dental distur-
bances, because it frequently includes high-dose chemother-
apy and total body irradiation [18].
The most common dental anomaly in the present study
was microdontia (33.7%). The prevalence of microdontia
ranges from 4% to 78% in CCS [4,8,15]. This variation is prob-
ably due to different ages at cancer diagnosis; younger 
patients were at a higher risk of microdontia. The prevalence
of microdontia in the present study clearly exceeded that in
Japanese children (1.9%), Iranian individuals aged below 20
years (2%), and Korean individuals (11.2%) [19-21]. The max-
illary premolar was most commonly affected by microdontia,
followed by the maxillary second molar. Of note, tooth age-
nesis and microdontia of the second premolars and second
molars occurred most frequently in children exposed before
3 years of age. The most common root malformation in the
present study was V-shaped roots (29.8%). Altered odonto-
blastic activity, a consequence of abnormal secretory function
of microtubules and complex changes in inter- and intracel-
lular relationships, can result in short, thin, and blunt roots.
Some chemotherapeutic agents such as vinblastine and vin-
cristine can affect mature secretory odontoblasts and amelo-
blasts.
This study has a number of strengths. It provided compre-
hensive clinical evaluations for the dental health status and
included a large number of CCS. The novel MDDI system we
developed was able to provide specific measurements for the
severity of damage to the permanent dentition. However, the
measurements of crown size based on clinical examination
were not considered as reliable. Dental plaster casts should
be used for accurate measurements. In addition, the hetero-
geneous nature of the clinical course of each case made it dif-
ficult to evaluate the differential dental effects according to
cancer treatment.
A multidisciplinary approach involving oncologists, pedi-
atric dentists, and other related health professionals is essen-
tial in caring for the child before, during and after any cancer
therapy. We recommend completion of a baseline dental
check as soon as the patient can cooperate in taking a pano-
ramic radiograph. The risk factors identified in this study can
help clinicians predict dental developmental disturbances.
For patients with a higher risk, it will be necessary to visit
the dental clinic at least every six months (or more often if
issues such as oral mucositis, xerostomia, or trismus are pres-
ent) [22]. Periodic surveillance facilitates detection of abnor-
mal tooth development, enabling pediatric dentists to inter-
vene earlier and promote a more aggressive treatment plan.
In cases of high dose HNRT to patients under 3 years, the use
of lead-lined stents, prostheses, and shields should be dis-
cussed with the radiation oncologist [22,23]. In addition, 
informed consent should include a discussion of the dental
developmental disturbances that can possibly occur as a 
result of the proposed cancer treatment. 
In conclusion, these results suggest that severe dental 
developmental disturbances were significantly associated
with a cancer diagnosis at  3 years of age, a history of HSCT,
the use of  4 classes of chemotherapeutic agents, and the use
of heavy metal agents. This study provides information that
can assist clinicians in early detection, prevention, and timely
intervention.
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